Biotechnology - Pharmaceutical, Sanofi

Filter

Current filters:

PharmaceuticalSanofi

Popular Filters

1 to 25 of 78 results

Sanofi appoints Dr Anne Beal as chief patient officer

Sanofi appoints Dr Anne Beal as chief patient officer

31-03-2014

French drug major Sanofi has announced the appointment of Anne Beal to the newly created position of…

BiotechnologyBoardroomFrancePharmaceuticalSanofiUSA

What does the future hold for pharma?

What does the future hold for pharma?

22-11-2013

Here's our take on the week's top stories.

AstraZenecaBayerBiotechnologyCerulean PharmaMarkets & MarketingPharmaceuticalResearchSanofi

Sanofi’s alirocumab monotherapy reduced LDL cholesterol three times more than ezetimibe

Sanofi’s alirocumab monotherapy reduced LDL cholesterol three times more than ezetimibe

16-10-2013

Sanofi and partner Regeneron Pharmaceuticals this morning released results from the Phase III ODYSSEY…

BiotechnologyCardio-vascularPharmaceuticalRegeneronResearchSanofi

UK's NICE calls for more information on MS treatment Aubagio

18-09-2013

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) is calling on Genzyme,…

AubagioBiotechnologyEuropeGenzymeNeurologicalPharmaceuticalPricingRegulationSanofi

Genzyme's MS drug Lemtrada approved in Europe

17-09-2013

French drug major Sanofi (Euronext: SAN) and its USA-based biotech subsidiary Genzyme revealed this morning…

AubagioBiotechnologyEuropeGenzymeLemtradaNeurologicalPharmaceuticalRegulationSanofi

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Sanofi's MS drug Aubagio gains final European approval

02-09-2013

Following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products…

AubagioBiotechnologyEuropeGenzymeNeurologicalPharmaceuticalRegulationSanofi

New Zealand to widen access for type 1 and type 3 Gaucher disease drug

07-08-2013

New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of a proposal to widen…

Asia-PacificBiotechnologyCerezymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Sanofi sees end to "patent cliff" doldrums, as it misses forecasts

01-08-2013

French drug major Sanofi (Euronext: SAN) posted second-quarter 2013 financial results this morning (August…

BiotechnologyFinancialGenzymePharmaceuticalSanofi

New entrants to multiple sclerosis market will drive 10% pa growth through 2018

26-07-2013

The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10%…

AbbVieAubagioBayerBiogen IdecBiotechnologydaclizumabGlobalLemtradaMarkets & MarketingNeurologicalocrelizumabPharmaceuticalRocheSanofiTecfidera

Regulatory briefs: Sanofi's Fluzone; Roche' RoActemra; Takeda's Rienso

10-06-2013

French pharma major Sanofi (Euronext: SAN) today (June 10) announced that the US Food and Drug Administration…

Anti-Arthritics/RheumaticsBiotechnologyPharmaceuticalRegulationRocheSanofiTakeda PharmaceuticalsVaccines

Negative late-stage trial results for Sanofi's iniparib and otamixaban

03-06-2013

There was disappointing news from French drug major Sanofi (Euronext: SAN) this morning (June 3), as…

BiotechnologyCardio-vasculariniparibOncologyotamixabanPharmaceuticalResearchSanofi

Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

22-05-2013

French drug major Sanofi (Euronext: SAN) and US biotech partner Regeneron Pharmaceuticals (Nasdaq: REGN)…

BiotechnologydupilumabPharmaceuticalRegeneronResearchRespiratory and PulmonarySanofi

Regeneron acquires rights to two ophthalmology programs from Sanofi

03-05-2013

US biotech firm Regeneron Pharmaceuticals (Nasdaq: REGN) has expanded its ophthalmology portfolio by…

BiotechnologyEyleaFinancialLicensingOphthalmicsPharmaceuticalRegeneronSanofi

Generics take toll on Sanofi's 1st-qtr sales, with net profit down 33.5%

02-05-2013

French drug major Sanofi (Euronext: SAN) today (May 2) reported first-quarter 2013 financial results…

BiotechnologyFinancialGenzymePharmaceuticalSanofi

Sanofi's Aubagio delayed onset of clinically definite MS in TOPIC study

25-04-2013

French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme announced today positive top-line…

AubagioBiotechnologyGenzymeNeurologicalPharmaceuticalResearchSanofi

BioTrends views Xeljanz and Zytiga prescribing in USA

26-03-2013

After around two months on the market, 37% of US rheumatologists have prescribed Pfizer's (NYSE: PFE)…

Anti-Arthritics/RheumaticsAstellas PharmaBiotechnologyJevtanaJohnson & JohnsonMedivationNorth AmericaOncologyPfizerPharmaceuticalSanofiXeljanzXtandiZytiga

Sanofi and Transgene collaborate on immunotherapy treatments; NAS designation of Aubagio disputed

25-03-2013

Drug major Sanofi (Euronext: SAN) and fellow France-based biotech firm Transgene SA (NYSE-Euronext: TNG)…

AubagioBiotechnologyEuropeGenzymeImmunologicalsNeurologicalPharmaceuticalProductionRegulationSanofiTransgene

1 to 25 of 78 results

Back to top